D-1161-2022 Class II Terminated

Recalled by PD-Rx Pharmaceuticals, Inc. — Oklahoma City, OK

FDA drug recall D-1161-2022 was initiated by PD-Rx Pharmaceuticals, Inc. on Jun 6, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 1441 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 6, 2022
Initiation Date
Jun 6, 2022
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1441 bottles

Product description

Losartan Potassium Tablets, USP 25 mg, 90 Tablets bottles, Rx Only Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc. Oklahoma City, OK 73127 Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex, Alathur, Kanchipuram-603 110, Tamilnadu, India NDC 72789-163-90 UPC 3 72789 16390 1

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Distribution pattern

Nationwide

Code information

Lots: D21C18 Exp. 09/30/22; E21A28 Exp. 09/30/22; E21C04 Exp. 09/30/22; E21D59 Exp. 09/30/22; G21B65 Exp. 09/30/22; H21A12 Exp. 09/30/22; H21D42 Exp. 09/30/22; K21D19 Exp. 10/31/22; A22A73 Exp. 10/31/22

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1161-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1161-2022. Report a data issue: hello@regdatalab.com.